Introduction Biogen(BIIB) is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. Biogen(BIIB) have a broad portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and co-developed two treatments to address a defining…
Month: January 2024
Sanofi(SNY): financial analysis for 2022 and Q3 2023.
Summary We reckon Sanofi(SNY) is worth €115 billion or $125.3 billion. Introduction Sanofi(SNY) is a leading global healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Sanofi(SNY) has three principal activities: Pharmaceuticals, Consumer Healthcare, and Vaccines. Pharmaceuticals segment have €30.69 billion, consumer healthcare segment have €5.08…
Bristol-Myers Squibb Company(BMY)：$50 per share is a good buying opportunity
Bristol-Myers Squibb(BMY)Q1 2024 Introduction Bristol-Myers Squibb Company(BMY) continues to operate in one segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb Company’ revenues come from products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Profitability analysis Bristol-Myers Squibb Company(BMY) reported $46.1…
AstraZeneca PLC(AZN): 2022 financial report and Q3 2023 earnings analysis
AstraZeneca PLC(AZN) in fiscal 2022 has six reportable products sales: Oncology($14.6 billion ), Cardiovascular, Renal & Metabolism($9.18 billion ), Respiratory & Immunology($5.76 billion ), Vaccines & Immune Therapies($4.7 billion ), Rare Disease ($7 billion )and other($1.6 billion ). Profitability analysis AstraZeneca PLC(AZN) reported total revenues of $44.3 billion, $37.4 billion and $26.6 billion in 2022,in…
Eli Lilly and Company(LLY)’market capitalization amount to approximately $600 billion ,and even PE is more than 100 times, which mean shareholders need to earn back their capital over a hundred year.
Introduction Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. The firm discover, develop, manufacture, and market products in a single business segment—human pharmaceutical products. The company’s products…
Johnson & Johnson(JNJ)’ financial analysis and value
Description of the Company and Business Segments Johnson & Johnson and its subsidiaries (the Company) have approximately 152,700 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health…
AbbVie(ABBV) is worth about $200 billion or $113.2 per share ,which is a good buy opportunity.
Company Overview(from AbbVie(ABBV)’s 2022 form 10k) AbbVie(ABBV)is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience and eye care. AbbVie’s products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned…
Amgen(AMGN) reported $19.99 billion in revenues in the nine months ended September 30,2023 and $19.4 billion in revenues in the nine months end September 30,2022.
Investment advice We reckon that $168 per share is a good buy point. Introduction Amgen(AMGN)operate in six commercial areas: inflammation, oncology/hematology, bone health, cardiovascular (CV) disease, nephrology and neuroscience. Amgen(AMGN) conduct discovery research primarily in three therapeutic areas: inflammation, oncology/hematology and general medicine. Profitability analysis Amgen(AMGN) reported total revenues $26.2 billion, $25.9 billion and…
Novartis AG(NVS) reported net sales of $34 billion in the nine months to September 30, 2023, up from $31.6 billion in the nine months to September 30,2022.
Summary We reckon that Novartis AG(NVS)’ stock price was overestimated ,and $73 per share is a good buy point. Introduction Novartis AG(NVS) is a multinational group of company specializing in the research, development, manufacturing and marketing of broad range of innovative pharmaceuticals and cost-saving generic medicines. Novartis AG(NVS), Swiss holding company, owns, directly or indirectly,…